Wire · opportunities
Alkermes eyes orexin ADHD drug as potential 'company changer'
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Alkermes has reported promising phase 1b clinical data for its orexin agonist ALKS 7290 in treating ADHD symptoms, showing significant symptom improvement and a favourable safety profile. The company is rapidly progressing to phase 2 trials and plans to extend studies into children, aiming to tap the large and growing ADHD market and potentially transform its business.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Alkermes is racing to expand its orexin agonist beyond sleep disorders into ADHD, opening a rare chance for CNS drug founders to enter a large, validated market fast. Your clinical and regulatory plans need immediate adaptation to keep pace with this emerging competitor and opportunity.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics